Does Big Soap Have Clean Hands?

Does Big Soap Have Clean Hands?

Soap companies don’t seem to think soap really gets people, or dishes, clean. About half the liquid soaps they sell in the U.S. are fortified with bacteria-killing chemicals.

Soap companies say an abundance of evidence shows that these products kill more germs than ordinary soap does. That’s debatable, but it’s not even the point. There’s no benefit to killing germs unless the result is less illness. And there is no good evidence that antimicrobials protect people’s health. And increasing evidence suggests they may help make germs more powerful.Over the next year, soapmakers will have to either prove their germ-killing products are safe and effective or else take them off the market, the Food and Drug Administration has ruled. This mandate comes decades later than it should have; the FDA first drafted the order 35 years ago. It took a lawsuit from the Natural Resources Defense Council to force the agency’s hand. Still, it is the right move.

The research so far suggests that soapmakers have an uphill climb to meet the FDA’s demand. In a 2007 survey of multiple studies, not a single one of four trials showed a significant reduction in illness symptoms in households that used antimicrobial soap.

The survey also cast doubt on the idea that these products are superior germ killers. In five of nine studies, those who washed with an antimicrobial had significantly fewer bacteria on their hands. Yet in four of those trials, the biocide used was two to 10 times as concentrated as is typical in consumer soaps. In the fifth study, the reduction in bacteria was achieved only when volunteers washed their hands for 30 seconds 18 times a day.

To continue selling antimicrobials, the soap industry will also have to address new indications that some of these products may be harmful.

The most common agent in antimicrobial soaps is triclosan, a chemical that is structurally similar to thyroid hormones and has been shown in animal studies to alter hormone regulation. Other studies suggest that triclosan and the related agent triclocarban may contribute to antibiotic resistance in bacteria that cause disease in humans. More than 2 million people fall ill with antibiotic-resistant infections in the U.S. each year, and at least 23,000 die. Research has shown that triclosan can enter the food chain through wastewater. It’s become so ubiquitous, 72 percent of Americans have triclosan residue in their urine.

These are hardly risks worth taking, absent strong evidence that antibacterial soaps make people healthier. If soap companies can’t prove their products work, the FDA should ban them.

To contact the Bloomberg View editorial board: view@bloomberg.net.

Unknown's avatarAbout bambooinnovator
Kee Koon Boon (“KB”) is the co-founder and director of HERO Investment Management which provides specialized fund management and investment advisory services to the ARCHEA Asia HERO Innovators Fund (www.heroinnovator.com), the only Asian SMID-cap tech-focused fund in the industry. KB is an internationally featured investor rooted in the principles of value investing for over a decade as a fund manager and analyst in the Asian capital markets who started his career at a boutique hedge fund in Singapore where he was with the firm since 2002 and was also part of the core investment committee in significantly outperforming the index in the 10-year-plus-old flagship Asian fund. He was also the portfolio manager for Asia-Pacific equities at Korea’s largest mutual fund company. Prior to setting up the H.E.R.O. Innovators Fund, KB was the Chief Investment Officer & CEO of a Singapore Registered Fund Management Company (RFMC) where he is responsible for listed Asian equity investments. KB had taught accounting at the Singapore Management University (SMU) as a faculty member and also pioneered the 15-week course on Accounting Fraud in Asia as an official module at SMU. KB remains grateful and honored to be invited by Singapore’s financial regulator Monetary Authority of Singapore (MAS) to present to their top management team about implementing a world’s first fact-based forward-looking fraud detection framework to bring about benefits for the capital markets in Singapore and for the public and investment community. KB also served the community in sharing his insights in writing articles about value investing and corporate governance in the media that include Business Times, Straits Times, Jakarta Post, Manual of Ideas, Investopedia, TedXWallStreet. He had also presented in top investment, banking and finance conferences in America, Italy, Sydney, Cape Town, HK, China. He has trained CEOs, entrepreneurs, CFOs, management executives in business strategy & business model innovation in Singapore, HK and China.

Leave a comment